Company / Revenue
Cartesian Therapeutics, Inc. Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$38.9M
FY2025
5-year range
$6.7M / $85.1M
FY2021-FY2025
Trend
+49.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue has fluctuated over the past 8 years, ranging from $207,000 in FY2019 to $85M in FY2023.
Based on SEC 10-K filings.
$39M in FY2025 with a 5-year CAGR of +112.3%.
Declined from $85M to $39M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- +32.8%
- 5-Year CAGR
- +112.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +112.3%, indicating consistent growth.
- In FY2025, revenue increased 49.6% year-over-year.
- Peak revenue was recorded in FY2023.
- Lowest revenue in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -0.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $38.9M | +49.6% |
| FY2024 | $26.0M | -69.4% |
| FY2023 | $85.1M | +412.6% |
| FY2022 | $16.6M | +148.6% |
| FY2021 | $6.7M | +639.4% |
| FY2020 | $903.0K | +336.2% |
| FY2019 | $207.0K | -93.2% |
| FY2016 | $3.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026